CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours

Most clinically applied cancer immunotherapies rely on the ability of CD8(+) cytolytic T cells to directly recognize and kill tumour cells(1–3). These strategies are limited by the emergence of major histocompatibility complex (MHC)-deficient tumour cells and the formation of an immunosuppressive tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruse, Bastian, Buzzai, Anthony C., Shridhar, Naveen, Braun, Andreas D., Gellert, Susan, Knauth, Kristin, Pozniak, Joanna, Peters, Johannes, Dittmann, Paulina, Mengoni, Miriam, van der Sluis, Tetje Cornelia, Höhn, Simon, Antoranz, Asier, Krone, Anna, Fu, Yan, Yu, Di, Essand, Magnus, Geffers, Robert, Mougiakakos, Dimitrios, Kahlfuß, Sascha, Kashkar, Hamid, Gaffal, Evelyn, Bosisio, Francesca M., Bechter, Oliver, Rambow, Florian, Marine, Jean-Christophe, Kastenmüller, Wolfgang, Müller, Andreas J., Tüting, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307640/
https://www.ncbi.nlm.nih.gov/pubmed/37316667
http://dx.doi.org/10.1038/s41586-023-06199-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307640/
https://www.ncbi.nlm.nih.gov/pubmed/37316667
http://dx.doi.org/10.1038/s41586-023-06199-x

Ejemplares similares